Amino acid alterations in EFG-G of methicillin-resistant <i>Staphylococcus sciuri</i>.

<p>Amino acid alterations in EFG-G of methicillin-resistant <i>Staphylococcus sciuri</i>.</p

Characteristics of methicillin-resistant <i>Staphylococcus sciuri</i> strains isolated from nasal and throat swab specimens obtained from hospitalised patients and healthcare workers (HCWs).

<p>Characteristics of methicillin-resistant <i>Staphylococcus sciuri</i> strains isolated from nasal and throat swab specimens obtained from hospitalised patients and healthcare workers (HCWs).</p

Presence of methicillin-resistant <i>Staphylococcus sciuri</i> in nasal and throat swab samples obtained from hospitalised patients and healthcare workers (HCWs).

<p>Presence of methicillin-resistant <i>Staphylococcus sciuri</i> in nasal and throat swab samples obtained from hospitalised patients and healthcare workers (HCWs).</p

Comparison of direct inoculation of MRSA-ID, ORSA, oxacillin-MSA and broth enrichment (BE) prior to inoculation on oxacillin-MSA in detection of methicillin-resistant <i>Staphylococcus sciuri</i> (MRSS) verified by identification by automated Vitek2 System and <i>mecA</i> PCR.

<p>Comparison of direct inoculation of MRSA-ID, ORSA, oxacillin-MSA and broth enrichment (BE) prior to inoculation on oxacillin-MSA in detection of methicillin-resistant <i>Staphylococcus sciuri</i> (MRSS) verified by identification by automated Vitek2 System and <i>mecA</i> PCR.</p

Distribution of methicillin-resistant <i>Staphylococcus sciuri</i> (MRSS) carriers and non-carriers among patients and healthcare workers (HCWs) stratified by department, gender, age group, patient underlying diagnosis and duration of hospitalisation at the Clinical Centre of Serbia, Serbia.

<p>Distribution of methicillin-resistant <i>Staphylococcus sciuri</i> (MRSS) carriers and non-carriers among patients and healthcare workers (HCWs) stratified by department, gender, age group, patient underlying diagnosis and duration of hospitalisation at the Clinical Centre of Serbia, Serbia.</p

Linkage disequilibrium-maps for A) <i>NLRP3</i>, B) <i>TLR5</i>, and C) <i>TLR10/1</i>.

<p>Numbers in squares represent r². Darker red indicates stronger linkage disequilibrium. Maps were made using Haploview software version 4.2 and CEPH/CEU HapMap dataset (Phase II+III merged, release 28/ August10). HapMap data were downloaded by respective genes (<i>TLR5</i> and <i>NLRP3</i>) and for <i>TLR10/1</i> data spanning both genes. To simplify LD-maps, SNPs were selected in the following way: NLRP3: minor allele frequency (MAF) >0.1, Hardy-Weinberg equilibrium (HW) p-value >0.01, genotype>50%, force include: rs10754558, force exclude #4–29; TLR5: MAF >0.1, HW p-value >0.01, genotype>50%, force include rs5744176, force exclude # 17–25; TLR10/1: MAF >0.1, HW p-value >0.01, genotype>50%, force include rs11096957, force exclude #4–58, 98–111.</p

Baseline clinical characteristics and treatment response of the study population.

<p>SD: standard deviation; DMARD: disease modifying anti-rheumatic drugs; VAS: visual analogue scale; ΔVAS: baseline VAS minus follow-up VAS; TJC: tender joint count; SJC: swollen joint count; HAQ: health assessment questionnaire; CRP: C-reactive protein; DAS28: disease activity score (28-joints); EULAR: European League Against Rheumatism; ACR50: American College of Rheumatology, 50% improvement; RelDAS28: relative change in DAS28;</p><p>^#: Two-sided t-test p-value of difference in means/proportions between seropositive and seronegative patients; Seropositive: Positive for IgM-RF</p><p>Baseline clinical characteristics and treatment response of the study population.</p

Odds ratio for association between polymorphisms in <i>IL18</i>, <i>NLRP3</i>, <i>TLR1</i> and <i>TLR5</i> and EULAR good/moderate vs. none and good vs. moderate/non-response, respectively.

<p>For <i>TLR5</i> rs5744174, patients were also stratified on diagnosis based on IgM-RF (seropositive-/seronegative RA). Log scale, 95% confidence interval.</p

Genotypes of associated polymorphisms and adjusted odds ratios for associations between gene variants and EULAR anti-TNF treatment response.

<p>Logistic regression, adjusted (Adj.) for sex, age, HAQ, CRP, DMARD at baseline, IgM RF status (seropositive/seronegative). CI: confidence interval, Freq.: Frequency, OR: odds ratio, EULAR: European League Against Rheumatism, P-value: *<0.05, **<0.01.</p

Adjusted odds ratio (OR) for associations between gene variants and ACR50 and relDAS28 response to anti-TNF treatment.

<p>Adj. OR: adjusted odds ratio for ACR50 and coefficient (Coeff.) for relative change in DAS28 (relDAS28). Adjusted for gender, age, HAQ-, DMARD at baseline, CRP, IgM RF status (seropositive/seronegative). Freq.: frequency.</p